Page last updated: 2024-12-11

flavasperone

Description

flavasperone: inhibits ACAT2; isolated from Aspergillus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

flavasperone : A naphtho-gamma-pyrone that is 4H-naphtho[1,2-b]pyran-4-one carrying a methyl substituent at position2, a hydroxy substituent at position 5 and two methoxy substotuents at positions 8 and 10. Originally isolated from Aspergillus niger. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5748546
CHEMBL ID4645135
CHEBI ID133814
SCHEMBL ID16226658
MeSH IDM0529481

Synonyms (19)

Synonym
unii-qus3f7kq3e
qus3f7kq3e ,
4h-naphtho(1,2-b)pyran-4-one, 5-hydroxy-8,10-dimethoxy-2-methyl-
asperxanthon
tmc 256c2
antibiotic tmc 256c2
CHEBI:133814
5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho[1,2-b]pyran-4-one
asperxanthone
flavasperone
3566-99-2
5-hydroxy-8,10-dimethoxy-2-methyl-4h-benzo[h]chromen-4-one
flavasperon
SCHEMBL16226658
DTXSID40189166
5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho[1,2-b]pyran-4-one, 9ci
tmd256c2
5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho(1,2-b)pyran-4-one
CHEMBL4645135
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
acyl-CoA:cholesterol acyltransferase 2 inhibitorA sterol O-acyltransferase inhibitor that specifically inhibits acyl-CoA:cholesterol acyltransferase 2.
Aspergillus metaboliteAny fungal metabolite produced during a metabolic reaction in the mould, Aspergillus.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
antiviral agentA substance that destroys or inhibits replication of viruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
naphtho-gamma-pyroneAny naphthopyran whose skeleton consists of a naphathalene ring system ortho-fused to a gamma-pyrone.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1651643Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Anti-inflammatory Metabolites from
AID1777026Anticancer activity against cisplatin-resistant human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of cisplatin by MTT assay
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.68 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
chemdatabank.com